Guerbet wins prostate cancer challenge
Bringing together more than 320 academic and industrial teams, including Guerbet, the challenge invites each team to submit an artificial intelligence algorithm capable of diagnosing more than 10,000 MRI examinations of the
prostate to be compared with the diagnoses of radiologists specialized in prostate imaging.
' This recognition testifies to our commitment to innovation and research to improve the diagnosis and management of cancer patients', reacted François Nicolas, Senior Vice-
President research, development and innovation, and Chief digital officer of Guerbet.
A first step towards commercializing the AI algorithm for prostate cancer will be made within the framework of the non-exclusive
license agreement signed with Intrasense, which provides for the commercialization of a product integrating the Guerbet prostate algorithm in the first half of 2024', he added.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction